Infertilità / Myo-Inositolo

Inositol safety clinical evidences

Myo-inositol is a six carbon cyclitol that contains five equatorial and one axial hydroxyl groups. Myo-inositol has been classified as an insulin sensitizing agent and it is commonly used in the treatment of the Polycystic Ovary Syndrome (PCOS). However, despite its wide clinical use, there is still scarce information on the myo-inositol safety …

More
Infertilità / Myo-Inositolo

Reflections on inositol(s) for PCOS therapy (Nestler-Unfer 2015)

In polycystic ovary syndrome (PCOS) pathogenesis, both the insulin resistance and the related compensatory hyperinsulinemia are involved. Despite their similarities, Myo-inositol (MI) and D-chiro-inositol (DCI) play different roles in PCOS etiology and therapy. Indeed, in tissue such as the liver both molecules are involved in the insulin signaling, i.e. MI promotes glucose uptake …

More
Infertilità / Pubblicazioni

PCOS Features, Diagnostic Criteria and Treatments

Polycystic ovary syndrome (PCOS) is one of the most common female endocrine disorder that affects 6–15% of the female population. It is a very complex syndrome that involves the hypothalamus, the pituitary gland, the ovaries, the adrenal gland and the peripheral adipose tissue that together contribute to create a generally imbalance, associated with …

More
Infertilità / Pubblicazioni

Polycystic ovary syndrome

Polycystic ovary syndrome (PCOS) is one of the most common female endocrine disorder that affects 6–15% of the female population. It is a very complex syndrome that involves the hypothalamus, the pituitary gland, the ovaries, the adrenal gland and the peripheral adipose tissue that together contribute to create a generally imbalance, associated with …

More
Infertilità / Myo-Inositolo

The Rationale of the Myo-Inositol and D-Chiro-Inositol Combined Treatment

PCOS is one of the most common endocrine disorders affecting women and it is characterized by a combination of hyper-androgenism, chronic anovulation, and insulin resistance. While a significant progress has recently been made in the diagnosis for PCOS, the optimal infertility treatment remains to be determined. Two inositol isomers, myo-inositol (MI) and D-chiro-inositol …

More
Infertilità / Myo-Inositolo

Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age. It is characterized by chronic anovulation, hyperandrogenism, and insulin resistance. It is the main cause of infertility due to the menstrual dysfunction and metabolic disorders. Women with PCOS also have an increased cardiovascular risk because of dyslipidemia and …

More
Infertilità / Myo-Inositolo

Hereditay hemorragic teleangectasia and pregnancy

We report an uncommon case of a 38-years-old pregnant woman affected by HHT (Hereditary haemorrhagic telangiectasia; OslerWeber-Rendu syndrome) who underwent to a caesarean section (CS) without any complication. The patient at 36th weeks+1 day pregnancy referred to the Emergency Obstetric Unit due to a intercostals pain on left side. On third day after …

More
Infertilità / Myo-Inositolo

Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use

Objective: Dose-dependent side effects related to myo-inositol (MI) oral administration represent a significant shortcoming for its clinical use. Aiming to search for a pharmaceutical form able to be better absorbed, the pharmacokinetic (PK) profile of the new manufactured MI soft gelatin capsule form was evaluated and compared with the commercially available MI powder.
Research design and methods: A …

More
Infertilità / Myo-Inositolo

Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use

 

Objective: Dose-dependent side effects related to myo-inositol (MI) oral administration represent a significant shortcoming for its clinical use. Aiming to search for a pharmaceutical form able to be better absorbed, the pharmacokinetic (PK) profile of the new manufactured MI soft gelatin capsule form was evaluated and compared with the commercially available MI powder.

More

  • 1
  • 2